For many pharmaceutical companies, the implementation of value-based healthcare (VBH) has started to feel like a direct attack on their current business models. This whitepaper looks at the implications of this trend for pharma companies, and outlines how they can shift corporate strategies in order to cope with, and eventually thrive in, this environment.
Download whitepaper to:
- Gain insights on preventing Health Technology Assessment (HTA) rejections
- Understand how the hard bargaining stance of HTA agencies and payors are affecting prices
- Understand how VBH markets are polarising and the impact on pharma revenue
- Plan for value through greater involvement in real-world use of pharma products